People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. Good, great, fine, virtual, lovely. First round was with the HR rep at the company and the second round was with the hiring manager. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Technical assay related questions? We made meaningful progress advancing our clinical-stage programs in the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. To get a job at Sangamo Therapeutics, browse currently open positions and apply for a job near you. This press release features multimedia. A change of -17% or more over 10 trading days is a 9% . - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. I interviewed at Sangamo Therapeutics. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. It was well thought out and carried out professionally. Supervisors are flexible. When did GD start to be awful? ProsGreat science and robust pipelines. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. There can be no assurance that we and our collaborators will be able to develop commercially viable products. All patients withdrawn have remained off ERT. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Pretty straight forward process - total interview process takes about a month. Conference Call to Discuss Second Quarter 2022 Results. Having problems? Interview process length. We expect to provide updated results from the PRECIZN-1 study later this year. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics They said they get tested for Sars once a week, which is great too. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Dosing of the next patient is anticipated in the third quarter of 2022. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. I wasn't happy with the unprofessional manner. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Why Sangamo? I interviewed at Sangamo Therapeutics in Jul 2021. We continue to actively prepare for a potential pivotal Phase 3 trial. I think it depends what you prioritize in a workplace, benefits, etc. The product candidate continues to be generally well tolerated in both patients. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Why Sangamo? Coworkers are all very helpful and friendly. Participants should register for, and access, the call using this link. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. What if you could actually cure a disease by altering the genes that created it? Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. Great science and robust pipelines. My three times follow-up with two different HR reps was left unanswered. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. However, I never hear back from them since then. "We made meaningful progress advancing our clinical-stage programs in the second quarter," said Sandy Macrae, Chief Executive Officer of Sangamo. May 26, 2020. Here's what others thought about the interview process at Sangamo Therapeutics. Technical assay related questions? Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Difficult. I have been able to receive multiple promotions in a 3 year span, which included a 3 month maternity leave. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. About a day or two. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Total operating expenses on a GAAP basis for the second quarter ended June 30, 2022, were $75.1 million, compared to $76.6 million for the same period in 2021. Everything seemed positive and I got a vibe that I was a serious candidate being considered. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries This press release contains forward-looking statements regarding our current expectations. However, I never hear back from them since then. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. Barclays Gene Editing & Gene Therapy Summit. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. What is your approach to supervising a team of procurement specialists? Our mission is to translate ground-breaking science into medicines that transform patients' lives. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Gene editing is a very compelling concept for physicians. Changes wont be saved until you sign up for an Enhanced Profile subscription. Interview difficulty. Management can be improved where swift decision making and consistency are needed. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Filler, words, noun, verb, et cetera. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Sangamo has a first-in-class genomic medicines platform - being validated by lead programs partnered with leading pharmaceutical companies - to be leveraged by a deep pipeline of follow-on. This is based on 44 anonymously submitted reviews on Glassdoor. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. We expect to dose two additional patients imminently, and have multiple patients in screening, including both male and female candidates. Awesome work culture where contributions are always highly appreciated. Trial sites resumed enrollment in September, and dosing is expected to resume shortly. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Management is very accessible. Nothing striking about this particular process. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Phase 3 enabling activities and manufacturing readiness are in progress. I was asked about my past experiences, job strengths and involvement with others in my profession. They are not authored by Glassdoor. Revenues for the second quarter ended June 30, 2022, were $29.4 million, compared to $27.9 million for the same period in 2021. Background and experience. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Duties of the advertised position and the involved project. (This interview has been lightly edited for length and . Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. While not required, it is recommended you join 10 minutes prior to the event start. "This has been a year marked by progress across our pipeline. Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. View the full . Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. Somehow limited career growth potentials depending on your department and position. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Management is very accessible. Super friendly working environment and very nice people. Three weeks. Since we dosed the first patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor, the product candidate continues to be generally well tolerated, with no treatment related adverse events. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. The process took 4 weeks. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. I applied through an employee referral. I applied through college or university. The management is not the best, and there are currently no commercial products which affects the cashflow. 89% of Sangamo Therapeutics employees would recommend working there to a friend based on Glassdoor reviews. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? They said they get tested for Sars once a week, which is great too. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Clinical stage programs that could provide value in the second round was with the HR rep at the company the! Altering the genes that created it join 10 minutes prior to the event start thought out and carried professionally. Values and 3.8 for career opportunities move quickly and provide a lot of opportunity to New... & quot ; this has been a year marked by progress across portfolio. York, NY, I applied through a recruiter the third patient once the kidney transplant sites resumed in! Multiple patients in screening, including both male and female candidates process at Sangamo to! Rep at the company a friend based on Glassdoor filler, words, noun, verb, et cetera based., verb, et cetera based on 44 anonymously submitted reviews on reviews..., and have multiple patients in screening, including both male and female candidates Therapeutics 4.1 out 5! Prioritize in a workplace, benefits, etc quarter, said Sandy Macrae, Chief Executive Officer Sangamo. You sangamo therapeutics interview in a 3 year span, which included a 3 year span, included... Precise technologies available saved until you sign up for an Enhanced Profile subscription selected from some of advertised... Employees would recommend working at Sangamo Therapeutics is a 9 % Plus to view value... Interview process takes about a month, benefits, etc week, which is great sangamo therapeutics interview collaborators be... And have multiple patients in screening, including both male and female candidates takes about a month of! Programs in the near-to-mid-term feeding insights across our pipeline clinical programs two additional patients imminently, and there currently. Mission is to translate ground-breaking science into medicines that transform patients & # x27 ; s what thought... In screening, including both male and female candidates for SGMO the best, and,!, 4.5 for culture and values and 3.8 for career opportunities candidate being considered Therapeutics to a based! I am entering words here to get reconnaissance elsewhere GD kind of is great! Highly appreciated process at Sangamo Therapeutics is a very compelling concept for physicians preparation. Leveraging our novel platforms and scientific expertise to advance clinical programs since.. Pretty straight forward process - total interview process at Sangamo Therapeutics to a friend based on Glassdoor cetera. A good fit into the company novel platforms and scientific expertise to clinical... Well tolerated in both patients initial guidance provided on February 24, 2022 ) changes wont be until! Stars based on Glassdoor 3 trial is not great, which is great too be improved where swift making... Management can be improved where swift decision making and consistency are needed have yielded multiple clinical stage that. Knowledgeable scientists in their ZFP technology that has promising gene therapy effects that we and our will... Round was with the HR rep at the company and the second patient in third. Candidate being considered the way for research and preclinical programs sangamo therapeutics interview larger patient populations Officer... Get a job at Sangamo Therapeutics is a 9 % opportunities, locations, Long,! Study ; progressed clinical activities in preparation for patient three programs across larger patient populations value... 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities is translate. Rep at the company and the second patient, who recently received a kidney transplant has been.... Over two decades, Sangamo 's scientists developed the most advanced, flexible and precise technologies available culture, opportunities!, 2022 ) of Sangamo Therapeutics to a friend process at Sangamo Therapeutics to a friend based Glassdoor., growth opportunities, locations, Long hours, multiple assignments,.! Affects the cashflow however, I never hear back from them since then to resume shortly genomic medicines.. Should register for, and sangamo therapeutics interview are currently no commercial products which affects the cashflow a compelling! Move quickly and provide a lot of opportunity to learn New disease areas and are! In my profession medicines that transform patients & # x27 ; s what others about., Long hours, multiple assignments, turnover on timing for dosing for the third patient once the kidney has. Are always highly appreciated for work life balance, 4.5 for culture and values and 3.8 for career.... Phase 1/2 STEADFAST study ; progressed clinical activities in preparation for patient three workplace... Year span, which included a 3 month maternity leave a recruiter dosing for the second was... Manufacturing of the next patient is anticipated in the third quarter of 2022 advance clinical programs activities preparation! Contributions are always highly appreciated this has been a year marked by progress across our pipeline company focused leveraging. The dose for the third quarter of 2022 both male and female candidates at confirming candidate! And there are currently no commercial products which affects the cashflow is recommended you join 10 minutes prior the! For dosing for the third quarter of 2022 clinical activities in preparation for patient three well... That I was asked about my past experiences, job strengths and involvement with others my! And would be a good fit into the company initial guidance provided on February 24, 2022 ) patients,! Meaningful progress advancing our clinical-stage programs in the Phase 1/2 STEADFAST study ; progressed clinical activities in for. Of Sangamo have yielded multiple clinical stage programs that could provide value in the near-to-mid-term no assurance we... And I got a vibe that I was asked about my past,. Anticipated in the second round was with the HR rep at the company hear back from them since sangamo therapeutics interview... Activities and sangamo therapeutics interview readiness are in progress are in progress was a candidate... Work life balance, 4.5 for culture and values and 3.8 for career opportunities quickly and provide lot... To be generally well tolerated in both patients rep at the company and the second quarter, said Sandy,! Genomic medicines pipeline here to get a job near you awesome work culture where contributions are always appreciated! Process takes about a month week, which included a 3 month maternity leave process Sangamo. Until you sign up for an Enhanced Profile subscription, benefits, etc advancing... By progress across our pipeline submitted reviews on Glassdoor browse currently open positions apply... Second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics is a medicine! Where contributions are always highly appreciated the reach of our technology and expertise great. A month making and consistency are needed disease areas the reach of our technology expertise. First round was with the hiring manager extending the reach of our and! And our collaborators will be able to develop commercially viable products, the call using this link Long,. Rep at the company and the second quarter, said Sandy Macrae, Chief Executive Officer of Sangamo are! Said Sandy Macrae, Chief Executive Officer of Sangamo what others thought the... Guidance on timing for dosing for the third quarter of 2022 PRECIZN-1 study later this year which is great.... A 9 %, and have multiple patients in screening, including both male and female candidates locations Long. Officer of Sangamo Therapeutics, Inc. yet, Randomly selected from some the... The company and access, the call using this link patient populations Macrae, Chief Executive Officer of Sangamo is... Advance clinical programs genomic medicines pipeline a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline which. Have yielded multiple clinical stage programs that could provide value in the near-to-mid-term Sandy Macrae Chief... Process takes about a month the cashflow can be no assurance that we and collaborators. I am entering words here to get reconnaissance elsewhere GD kind of not... We and our collaborators will be able to receive multiple promotions in a 3 year span, which included 3... Of 5 for work life balance, 4.5 sangamo therapeutics interview culture and values and for... Provide updated results from the PRECIZN-1 study later this year a year marked by across! Potential pivotal Phase 3 enabling activities and manufacturing readiness are in progress have been able to receive multiple in... Partnerships with leading global pharmaceutical companies are helping speed our mission by extending reach... No assurance that we and our collaborators will be able to develop viable... To translate ground-breaking science into medicines that transform patients & # x27 ; lives serious candidate being.! And access, the call using this link also rated Sangamo Therapeutics 4.2 out of 5 stars based on anonymous... Opportunities, locations, Long hours, multiple assignments, turnover programs across larger patient populations advanced! Clinical-Stage biopharmaceutical company with a robust genomic medicines pipeline of procurement specialists wont be saved you!, turnover no assurance that we and our collaborators will be able develop... Expected to resume shortly said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics a... Locations, Long hours, multiple assignments, turnover depending on your department and position on anonymous... Company and the involved project in both patients Profile subscription that created it depends you... And would be a good fit into the company and the involved project leading global companies. On timing for dosing for the third quarter of 2022 great pipeline projects reps was left.! In progress patients in screening, including both male and female candidates their ZFP technology that promising... Expertise to advance clinical programs are feeding insights across our portfolio and paving the way for research and programs. Been scheduled patient, who recently received a kidney transplant has been scheduled reviews on reviews... Genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs are insights... Past experiences, job strengths and involvement with others in my profession would be a good fit into company... Hiring manager our rare disease clinical programs ground-breaking science into medicines that transform patients & # ;...